Oxford Glyco Gaucher data

Oxford GlycoSciences (LSE:OGS) published in The Lancet results of its 1-year, 28-patient international Phase I/II open label trial showing improvements in Gaucher patients receiving 100 mg OGT 918 three times per day. The compound is an oral inhibitor of the glucosyltransferase enzyme. Patients in the trial were either unable or unwilling to receive intravenous glucocerebrosidase enzyme replacement therapy for the disease.

At 1 year, treated patients had a 12 percent reduction in meanliver volume (p<0.001) and a 19 percent reduction in spleenvolume (p<0.001). The trial also showed a 16.4 percent reduction in levels of chitotriosidase, a protein marker for disease activity(p<0.001). Side effects included diarrhea. ...